FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:208-209 July 18, 1996 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Rees, J. H. PubMed Citation

To the Editor: Rees et al. (Nov. 23 issue)¹ reported that patients with the Guillain–Barré syndrome and recent infection with Campylobacter jejuni have a more severe residual disability after one year than patients without C. jejuni infection. In later studies they showed that patients with the combination of C. jejuni infection and antibodies against GM1 ganglioside have the worst prognosis.² The effect of treatment was not included in their analyses, however.

We studied the outcome in 147 patients with Guillain–Barré syndrome six months after their enrollment in a trial comparing plasma exchange with intravenous immune globulin.³ None of the patients . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Prendergast, M. M., Moran, A. P. (2000). Review: Lipopolysaccharides in the development of the Guillain-Barre syndrome and Miller Fisher syndrome forms of acute inflammatory peripheral neuropathies. Innate Immunity 6: 341-359 [Abstract]  
• Sorensen, P. S. (1999). Intravenous Immunoglobulin Treatment in Neurologic Disorders: Yes. Arch Neurol 56: 1025-1027 [Full Text]  
• Nachamkin, I., Allos, B. M., Ho, T. (1998). Campylobacter Species and Guillain-Barre Syndrome. Clin. Microbiol. Rev. 11: 555-567 [Abstract] [Full Text]